Therefore, patient-driven tumor models combined with transgenic animal models are needed to further confirm whether inhibition of the PPARA-SL47A1 pathway is a potential strategy to enhance ferroptosis-mediated tumor suppression. This evidence concerns the gene PPARA and neoplasm.